Table 5 Study 205: Mean (X) and
Mean Change (∆) from Baseline in HAMD Depressed Mood Item #1 |
|||||||||||||||||||
LAST OBSERVATION CARRIED FORWARD
ANALYSIS |
|||||||||||||||||||
Treatment
Week: |
Baseline |
Wk 1 |
Wk 2 |
Wk 3 |
Wk 4 |
Wk 5 |
Wk 6 |
Wk 7 |
Wk 8 |
||||||||||
Treatment
Groups |
N |
X |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
|
BUP
SR 100 (VL) |
112 |
2.8 |
107 |
-0.3 |
112 |
-0.6 |
112 |
-0.8 |
112 |
-1.0 |
112 |
-1.1 |
112 |
-1.2 |
112 |
-1.2 |
112 |
-1.2 |
|
BUP
SR 200 (L) |
114 |
2.7 |
106 |
-0.3 |
114 |
-0.5 |
114 |
-0.7 |
114 |
-0.8 |
114 |
-0.9 |
114 |
-1.0 |
114 |
-1.0 |
114 |
-1.1 |
|
BUP
SR 300 (M) |
111 |
2.8 |
106 |
-0.4 |
111 |
-0.5 |
111 |
-0.7 |
111 |
-0.8 |
111 |
-0.9 |
111 |
-0.9 |
111 |
-1.0 |
111 |
-1.0 |
|
BUP
SR 400 (II) |
111 |
2.8 |
108 |
-0.2 |
111 |
-0.6 |
111 |
-0.7 |
111 |
-1.0 |
111 |
-1.0 |
111 |
-1.0 |
111 |
-1.0 |
111 |
-1.2 |
|
Placebo
(P) |
116 |
2.9 |
109 |
-0.3 |
116 |
-0.6 |
116 |
-0.7 |
116 |
-0.8 |
116 |
-0.9 |
116 |
-0.9 |
116 |
-1.0 |
116 |
-1.0 |
|
VL.
vs P |
2-sided p-values for pairwise compar- isons |
> 0.05 |
0.9 |
0.9 |
0.4 |
0.2 |
0.1 |
0.04 |
0.1 |
0.2 |
|||||||||
L
vs. P |
< 0.005 |
0.8 |
0.1 |
0.9 |
0.8 |
1.0 |
0.4 |
0.8 |
0.6 |
||||||||||
M
vs. P |
> 0.05 |
0.7 |
0.4 |
0.8 |
0.7 |
0.8 |
0.9 |
0.9 |
0.8 |
||||||||||
II
vs. P |
> 0.1 |
0.2 |
0.6 |
0.6 |
0.1 |
0.2 |
0.4 |
0.6 |
0.3 |
||||||||||
OBSERVED CASES ANALYSIS |
|||||||||||||||||||
Treatment
Week: |
Baseline |
Wk 1 |
Wk 2 |
Wk 3 |
Wk 4 |
Wk 5 |
Wk 6 |
Wk 7 |
Wk 8 |
||||||||||
Treatment
Groups |
N |
X |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
|
BUP
SR 100 (VL) |
112 |
2.8 |
107 |
-0.3 |
103 |
-0.6 |
102 |
-0.8 |
89 |
-1.0 |
85 |
-1.2 |
86 |
-1.3 |
82 |
01.4 |
76 |
-1.4 |
|
BUP
SR 200 (L) |
114 |
2.7 |
106 |
-0.3 |
100 |
-0.5 |
95 |
-0.7 |
90 |
-0.8 |
85 |
-1.0 |
83 |
-1.1 |
80 |
-1.2 |
74 |
-1.2 |
|
BUP
SR 300 (M) |
111 |
2.8 |
106 |
-0.4 |
98 |
-0.6 |
81 |
-0.9 |
80 |
-1.1 |
77 |
-1.1 |
71 |
-1.2 |
69 |
-1.3 |
66 |
-1.3 |
|
BUP
SR 400 (II) |
111 |
2.8 |
108 |
-0.2 |
94 |
-0.6 |
88 |
-0.8 |
83 |
-1.1 |
77 |
-1.2 |
75 |
-1.3 |
72 |
-1.4 |
70 |
-1.6 |
|
Placebo
(P) |
116 |
2.9 |
109 |
-0.3 |
107 |
-0.6 |
102 |
-0.7 |
90 |
-1.0 |
87 |
-1.1 |
83 |
-1.1 |
82 |
-1.2 |
75 |
-1.3 |
|
VL.
vs P |
2-sided p-values for pairwise compar- isons |
> 0.05 |
0.9 |
0.8 |
0.2 |
0.5 |
0.7 |
0.2 |
0.3 |
0.3 |
|||||||||
L
vs. P |
< 0.005 |
0.8 |
0.2 |
0.7 |
0.3 |
0.3 |
0.8 |
0.9 |
0.7 |
||||||||||
M
vs. P |
> 0.05 |
0.7 |
0.7 |
0.1 |
0.2 |
0.8 |
0.6 |
0.6 |
0.7 |
||||||||||
II
vs. P |
> 0.1 |
0.2 |
0.9 |
0.2 |
0.07 |
0.2 |
0.1 |
0.2 |
0.05 |
Bupropion
Sustained-Release Clinical Review 57
Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main
Index